Abstract submission is closed
Author notifications due 13 July
Early Bird registration closing 31 August
Professor Olli Kallioniemi
Olli Kallioniemi is Professor in Molecular Precision Medicine at the Karolinska Institutet and Director of the Science for Life Laboratory (www.SciLifeLab.se), a national infrastructure for life sciences in Sweden since 2015.
Professor Kallioniemi received his M.D. in 1984, Ph.D. in 1988 and specialty training in laboratory medicine at the University of Tampere in Finland. He undertook a postdoc at UC San Francisco in 1990-1992 and was appointed faculty at the National Human Genome Research Institute, at the NIH (1995-2002). He was the founding director of the Medical Biotechnology unit at Turku, Finland at the VTT Technical Research Centre and University of Turku (2002-2008). He was the Founding Director of FIMM – the Institute for Molecular Medicine Finland (www.fimm.fi) and professor at the University of Helsinki in 2007-2015. FIMM is part of the Nordic EMBL partnership in Molecular Medicine.
Professor Kallioniemi is an author of 367 publications, a member of the editorial board of six journals and has been an invited key note lecturer in over 150 meetings during the past five years. He has supervised 23 doctoral theses and has been an advisor to 27 postdocs. Professor Kallioniemi is an inventor and co-inventor of 24 issued patents, with a focus on diagnostic technology development, such as FISH, CGH, tissue microarrays, cell-based RNAi microarrays and bioinformatic methods. His current research is focussing on individualized systems medicine to promote precision care of cancer patients.
Dr Susan Chang
Susan Chang, MD, is the Director of the Neuro-Oncology Division at the University of California at San Francisco (UCSF), and she specializes in the treatment of adults with brain tumors. Dr. Chang received a medical degree from the University of British Columbia and completed a residency in internal medicine at Toronto General Hospital in Canada. She completed a fellowship in medical oncology at Princess Margaret Hospital in Toronto as well as a fellowship in neuro-oncology at the UCSF, where she later joined the faculty.
Dr. Chang performs clinical trials about brain tumor therapy protocols and experimental therapeutic regimens for adult patients. In addition to research into developing novel and effective therapeutic strategies for the treatment of patients with primary brain tumors, her research goals have expanded to include the evaluation of novel imaging techniques that may influence treatment selection for patients. She is the co-PI of a program project grant evaluating imaging and tissue biomarkers of glioblastoma and has recently been co-recipient of a SPORE project for evaluating the role of magnetic resonance spectroscopy in diagnosing tumors and evaluating therapeutic interventions. Dr. Chang has developed a caregiver program for patients with brain tumors at UCSF and is the editor in chief of a newly launched journal Neuro-Oncology Practice that focuses on the clinical aspects of the management of patients with an emphasis on quality of life and neuro-cognitive function.
On behalf of the Organising Committee, we would like to extend an invitation to all researchers and clinicians to join us at the 2018 Sydney Cancer Conference (SCC2018), being held at the International Convention Centre in Sydney on 11 & 12 October 2018.
SCC2018 will be the sixth Sydney Cancer Conference and will be co-hosted by the University of Sydney, Macquarie University, Newcastle University, the University of Technology, Canberra University and Western Sydney University.
SCC2018 will foster the development of our future generation of cancer researchers, and provide a national forum to showcase emerging research and areas of strength in cancer research across Australia.
The theme of the conference is “Bridging research and practice”, which reflects the various elements of cancer research along the translational research continuum. The program will feature all areas of cancer research – basic biomedical, public health, clinical and psychosocial – making the latest information and research available to delegates.
We hope you can join us in Sydney for this unique multi-disciplinary and multi-institutional cancer conference.
Dr Jenny Wang and A/Prof Roger Bourne
Co-Chairs, Sydney Cancer Conference 2018
SCC2018 will be taking place at the International Convention Centre, Sydney (ICC Sydney). ICC Sydney is at the heart of its very own Sydney Harbour waterfront precinct, set amongst restaurants, retail and a vibrant public domain on Darling Harbour.
Click here to view more information on the International Convention Centre, Sydney.